Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 11/20 | 0.50 |
| ▸ | KDR | P35968 | 7/20 | 0.50 |
| ▸ | EPHB4 | P54760 | 6/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.49 |
| ▸ | ENPP1 | P22413 | 4/20 | 0.47 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.45 |
| ▸ | FLT1 | P17948 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3132212 | 1.00 | EPHA2 (0.50) | EPHA2KDREPHB4ERBB2ENPP1 | |
| SCHEMBL6611547 | 1.00 | EPHA2 (0.50) | EPHA2KDREPHB4ERBB2ENPP1 | |
| SCHEMBL6408800 | 0.90 | EPHA2 (0.52) | EPHA2KDREPHB4ERBB2ENPP1 | |
| SCHEMBL17179600 | 0.83 | EPHA2 (0.52) | EPHA2KDREPHB4ERBB2ENPP1 | |
| SCHEMBL664787 | 0.83 | EPHA2 (0.52) | EPHA2KDREPHB4ERBB2ENPP1 | |
| SCHEMBL3132645 | 0.83 | EPHA2 (0.55) | EPHA2KDREPHB4ERBB2ENPP1 | |
| SCHEMBL4225415 | 0.81 | EPHA2 (0.70) | EPHA2KDREPHB4ERBB2MAPK1 | |
| SCHEMBL4225418 | 0.81 | EPHA2 (0.70) | EPHA2KDREPHB4ERBB2MAPK1 | |
| SCHEMBL4225735 | 0.81 | EPHA2 (0.70) | EPHA2KDREPHB4ERBB2MAPK1 | |
| SCHEMBL5214519 | 0.79 | ENPP1 (0.52) | EPHA2KDREPHB4ERBB2ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399667-B2 | 4-anilino quinazoline derivatives as antiproliferative agents | ASTRAZENECA AB (GB) | 2013-03-19 | — | — | US | disclosed |
| US-20130005727-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2013-01-03 | — | — | US | disclosed |
| EP-1487806-B1 | 4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | ASTRAZENECA AB (SE) | 2010-07-07 | — | — | EP | disclosed |
| US-20100152442-A1 | 4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | ASTRAZENECA AB | 2010-06-17 | — | — | US | disclosed |
| US-20080269487-A1 | 4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | ASTRAZENECA AB | 2008-10-30 | — | — | US | disclosed |
| US-20050215574-A1 | 4-anilino quinazoline derivatives as antiproliferative agents | ASTRAZENECA AB (SE) | 2005-09-29 | — | — | US | disclosed |
| EP-1487806-A1 | 4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | Astrazeneca AB (SE) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003082831-A1 | 4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005727-A1 | QUINAZOLINE DERIVATIVES | ABL1, ERBB2, EGFR | EPHA2 564/4885KDR 188/4885EPHB4 1549/4885 |
| US-20050215574-A1 | 4-anilino quinazoline derivatives as antiproliferative agents | ERBB2, ERBB4, EGFR | EPHA2 317/4885KDR 70/4885EPHB4 922/4885 |
| US-20080269487-A1 | 4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | ERBB2, ERBB4, EGFR | EPHA2 317/4885KDR 70/4885EPHB4 922/4885 |
| US-20100152442-A1 | 4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | ERBB2, ERBB4, EGFR | EPHA2 317/4885KDR 70/4885EPHB4 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.